SGLT-2 inhibitors cut hospitalisations and deaths
Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce heart failure hospitalisations by more than a third and halve all-cause mortality compared to other glucose-lowering treatments in type 2 diabetes, according to new research presented at the American College of Cardiologyâ€™s meeting in Washington.
Sponsor AstraZeneca says the study is â€œthe first large real-world evidence study of its kindâ€ comparing SGLT-2 inhibitors and other type 2 diabetes medicines.
The study used databases from six countries (the US, Norway, Denmark, Sweden, Germany and the UK) to match 154,523 type 2 diabetes patients taking SGLT-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin) with the same number of controls taking other glucose-lowering drugs.
Most patients (87 per cent) did not have a history of cardiovascular disease. There were 961 hospitalisations for heart failure across the six countries. The German database did not yield linked mortality but in the remaining five countries, 1,334 of 215,622 patients died.
Treatment with a SGLT-2 inhibitor reduced hospital-isations for heart failure by 39 per cent (hazard ratio [HR] 0.61) and deaths from any cause by 51 per cent (HR 0.49) compared with other type 2 diabetes medicines. SGLT-2 inhibitors reduced the composite of heart failure hospitalisation or death from any cause by 46 per cent. There was no significant difference by country.
The study did not examine other cardiovascular events, such as myocardial infarction and stroke, or focus on safety. Moreover, the authors also note that experience with SGLT-2 inhibitors â€œin real-world practice is still relatively shortâ€. Longer-term follow-up is therefore needed to determine whether the benefits are sustained.
Record my learning outcomes
Inspiring stories related to health, fitness and the pursuit of wellbeing
More like this
Does OTC NRT still have a role in smoking cessation?
E-cigarettes and varenicline are associated with higher abstinence rates than other smoking cessation aids including NRT.
1 Min Article
Pain conversations - making effective recommendations
Explore our detailed case studies to help understand how to advise customers on different causes of pain.
15 Min Module
Relief from the nasal symptoms of allergy
With NHS England advising that OTC products should no longer be prescribed to treat mild-to-moderate hayfever, pharmacy’s role in supporting sufferers is more important than ever. This module includes self-care advice and product recommendations to aid customer conversations.
5 Min Module
This module will help the pharmacy team to understand erectile dysfunction and its causes, and supply Viagra Connect to male customers affected by it, where appropriate
10 Min Module